OPTIMIZING THE USE OF RISK FACTORS TO GUIDE THE COST-EFFECTIVE USE OF PALIVIZUMAB PROPHYLAXIS AGAINST SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN INFANTS BORN 32-35 WEEKS' GESTATIONAL AGE

被引：0
|
作者：
Keary, I [1 ]
Kang, J. M. [2 ]
Paes, B. [3 ]
Rodgers-Gray, B.
Fullarton, J. [1 ]
Tarride, J. E.
Yang, H. J. [4 ]
Chang, Y. S. [5 ]
Carbonell-Estrany, X. [6 ]
机构：
[1] Violicom Med Ltd, Reading, Berks, England
[2] Yonsei Univ, Severance Childrens Hosp, Coll Med, Seoul, Gyeonggi, South Korea
[3] McMaster Univ, Hamilton, ON, Canada
[4] Soonchunhyang Univ Seoul Hosp, Seoul, Gyeonggi, South Korea
[5] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, Gyeonggi, South Korea
[6] Hosp Clin Barcelona, Barcelona, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE390
引用
收藏
页码：S125 / S125
页数：1
相关论文
共 31 条
  • [1] ASSESSMENT OF THE COST-EFFECTIVENESS OF RISK FACTOR GUIDED PROPHYLAXIS WITH PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTION IN COLOMBIAN INFANTS BORN AT 32-35 WEEKS' GESTATIONAL AGE
    Rodriguez-Martinez, C. E.
    Ordonez, J.
    Carbonell-Estrany, X.
    Fullarton, J.
    Keary, I
    Rodgers-Gray, B.
    D'Apremont, I
    Espinosa, S. M.
    Ribeiro, P. A.
    Stein, R.
    Vain, N.
    Tarride, J. E.
    Paes, B.
    VALUE IN HEALTH, 2023, 26 (12) : S156 - S156
  • [2] Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32-35 weeks' gestational age with more informed use of risk factors?
    Carbonell-Estrany, Xavier
    Fullarton, John R.
    Rodgers-Gray, Barry S.
    Gooch, Katherine L.
    Vo, Pamela G.
    Figueras-Aloy, Jose
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2015, 28 (10): : 1133 - 1141
  • [3] Impact of the risk scoring model on the cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks in Canada
    Lanctot, K. L.
    Paes, B.
    Francis, P. L.
    Chiu, A.
    Hui, C.
    Oh, P., I
    VALUE IN HEALTH, 2008, 11 (03) : A248 - A249
  • [4] The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Lanctot, Krista L.
    Masoud, Shababa T.
    Paes, Bosco A.
    Tarride, Jean-Eric
    Chiu, Aaron
    Hui, Charles
    Francis, Philip L.
    Oh, Paul I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3223 - 3237
  • [5] Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age
    Franklin, Jeremy A.
    Anderson, Evan J.
    Wu, Xionghua
    Ambrose, Christopher S.
    Simoes, Eric A. F.
    OPEN FORUM INFECTIOUS DISEASES, 2016, 3 (03):
  • [6] Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Robinson, Joan L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1631 - 1632
  • [7] Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Reply
    Lanctot, Krista L.
    Paes, Bosco
    Hui, Charles
    Chiu, Aaron
    Tarride, Jean-Eric
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (07) : 1632 - 1633
  • [8] Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants
    Paes, Bosco
    Lanari, Marcello
    Rodgers-Gray, Barry
    Fullarton, John
    Carbonell-Estrany, Xavier
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [9] A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age
    Keary, Ian P.
    Ravasio, Roberto
    Fullarton, John R.
    Manzoni, Paolo
    Lanari, Marcello
    Paes, Bosco A.
    Carbonell-Estrany, Xavier
    Baraldi, Eugenio
    Tarride, Jean-Eric
    Rodgers-Gray, Barry
    PLOS ONE, 2023, 18 (08):
  • [10] Burden of respiratory syncytial virus hospitalisation among infants born at 32-35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies
    Lanari, M.
    Anderson, E. J.
    Sheridan-Pereira, M.
    Carbonell-Estrany, X.
    Paes, B.
    Rodgers-Gray, B. S.
    Fullarton, J. R.
    Grubb, E.
    Blanken, M.
    EPIDEMIOLOGY AND INFECTION, 2020, 148
1234